Clinical Strength in Digital Health Executive Summary – Introduction
This report is the executive summary of the Clinical Strength in Digital Health report. Click here to download the full report
About the Full Report
Galen Growth has introduced the Evidence Signal to evaluate the Clinical Strength of a venture based on the number of clinical trials, regulatory filings and peer-reviewed publications that a venture has generated to confirm the medical benefit of its solution to the target customer.We are pleased to share with you our latest ecosystem analysis on the Clinical Strength of ventures across the 5 major global regions. We define the boundaries of this important topic and explain the current trends in the market that are driving demand in the area. Our analysis focuses on private ventures and includes noteworthy partnerships, spotlight ventures, and venture funding.With unmatched, unparalleled and indispensable coverage of the globe’s Digital Health ecosystems, this report is powered by HealthTech Alpha, a Galen Growth proprietary solution, and the world’s leading on-demand Digital Health private market data, intel and insights platform.
Contents
- Introduction to Clinical Strength in Digital Health
- Ecosystem Insights
- Partnerships
- Top Digital Health Clusters by Venture Clinical Strength
- Top Therapeutic Areas by Venture Clinical Strength
- Investment Insights
- Deep Dives into Clinical Strength of Regional Ecosystems
- Noteworthy Digital Health Partnerships, Venture Funding Deals and Exits
Key Insights
A first-of-a-kind study with 12,000+ ventures across 5 regional ecosystems have been analysed in this report to reveal that the growth of evidence for Clinical Strength is growing at a 5-year CAGR of 40%, or 4x the growth of new ventures.
Ecosystem evaluation by Digital Health Clusters shows that over 35% of ventures with solutions in the top 2 clusters: Medical Diagnostics and Remote Devices, have established clinical evidence for their solutions, whereas other clusters, such as Health Services Search, have a single-digit share of ventures with established Clinical Strength, as they likely do not require such evidence.
Respiratory Diseases and Cardiovascular Diseases took the top spots for therapeutics areas with the highest share of ventures with established Clinical Strength, with 45% and 40% respectively.
The Data Behind the Report
Within HealthTech Alpha, we have assessed more than 1,400 Digital Health ventures with an Evidence Signal > 40. An Evidence Signal of >40 indicates that the venture has generated evidence to confirm the medical benefit of their solution to the target customer.
To access all data visit https://healthtechalpha.com/hubpage/top-clinical-digital-health-ventures.
Source of Data
HealthTech Alpha, Galen Growth’s proprietary on-demand platform, is the data source for this report. HealthTech Alpha contains more than 200 million data points and hence is the leading Digital Health intelligence and analytics platform! Moreover, its coverage exceeds 12,000 Digital Health ventures globally. To find out more about our data, visit https://www.healthtechalpha.com/, or visit https://www.galengrowth.com/research for our reports.
